ModerateClass III antiarrhythmics (Vaughan Williams)×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Amiodarone and its metabolite desethylamiodarone inhibit P-gp. According to the amiodarone SmPC, plasma levels of P-gp substrates are expected to rise when they are given with amiodarone (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone 400 mg once daily with edoxaban 60 mg once daily raised the edoxaban area under the concentration–time curve (AUC) by 40% and peak concentration by 66% (edoxaban SmPC, EMA). This rise was not considered clinically significant. In the ENGAGE AF-TIMI 48 trial in non-valvular atrial fibrillation, edoxaban efficacy and safety were similar with and without amiodarone (edoxaban SmPC, EMA). Because of the long half-life of amiodarone, interactions can occur for several months after it is stopped (amiodarone SmPC, AEMPS).
Symptoms
Edoxaban increases the risk of bleeding and can cause severe, potentially fatal bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, vaginal bleeding, and bleeding into the skin and soft tissues (edoxaban SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock of unknown cause (edoxaban SmPC, EMA).
Management
The combination is not contraindicated, and amiodarone does not call for a lower edoxaban dose. The European edoxaban summary of product characteristics (SmPC) recommends 60 mg once daily unless there is another reason for 30 mg once daily. The other reasons are creatinine clearance of 15–50 mL/min, body weight of 60 kg or less, or ciclosporin, dronedarone, erythromycin or ketoconazole (edoxaban SmPC, European Medicines Agency, EMA). According to the US label, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors either (edoxaban label, US Food and Drug Administration, FDA). In the European Heart Rhythm Association practical guide, the pair is marked yellow (EHRA 2021). Edoxaban exposure rises by 40%. EHRA states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include age 75 years or older, chronic kidney disease, antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, and previous bleeding or a predisposition to it (EHRA 2021). Watch for signs of bleeding and anaemia during treatment. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Interactions with amiodarone can persist for several months after it is stopped (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Check creatinine clearance at the start of treatment in all patients and later when clinically indicated (edoxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2